Wednesday, January 11, 2023 7:56:28 PM
Lizzy, as a response to you and some others that responded to my earlier post:
First off, I am 100% going to vote in favor of Denner if and when it comes to the vote.
What I am saying is that I am not entirely comfortable with turning over COMPLETE control of the company to someone (anyone) that has not clearly articulated their intentions.
We do not know what Denner's intentions are. Someone stated that "his intentions are to get the company sold ASAP." Ummmm, no, I don't think that's true. And he has STATED in the past that he takes his time, and is never in a rush to get a company sold. So this "process" could take 3 years. But we just don't know.
What if (and this is a massive "IF") his intentions are to take the company private at $5 a share? Sure, some people here will be thrilled! But many of us will NOT be thrilled. I did NOT waste my time and my investment dollars to get 5 bucks, and watch some hedge fund turn around and sell HIS new company to Novartis for 25 bucks.
Do I think that will happen? No. Pretty sure it won't. But again - we do NOT know.
The bottom line is, if Denner gets SEVEN board seats, we are putting COMPLETE control in his hands, with NO idea what his plan is for the company.
So again, I'm voting for Denner's recommendation no matter what. But I *think* I might be more comfortable if Amarin offered him TWO board seats, and he accepted.
Now, if Denner comes out and clearly articulates what he would like to see happen (more than just "we need them to move faster and focus on cost containment, blah blah blah") prior to the proxy vote (and I like what I hear), then I might be inclined to be VERY supportive of total board control. But I really wish Denner would better articulate what his intentions are.
And please don't tell me "Denner's intentions are to maximize stockholder value". That's a given. He's a hedge fund manager, of course that's what he wants. But that doesn't articulate anything concrete. Despite what everything thinks, the Board and Management's intentions are to maximize shareholder value too. They just haven't done a great job of it yet. I just want to be sure that Denner is not going cause more harm than good.
First off, I am 100% going to vote in favor of Denner if and when it comes to the vote.
What I am saying is that I am not entirely comfortable with turning over COMPLETE control of the company to someone (anyone) that has not clearly articulated their intentions.
We do not know what Denner's intentions are. Someone stated that "his intentions are to get the company sold ASAP." Ummmm, no, I don't think that's true. And he has STATED in the past that he takes his time, and is never in a rush to get a company sold. So this "process" could take 3 years. But we just don't know.
What if (and this is a massive "IF") his intentions are to take the company private at $5 a share? Sure, some people here will be thrilled! But many of us will NOT be thrilled. I did NOT waste my time and my investment dollars to get 5 bucks, and watch some hedge fund turn around and sell HIS new company to Novartis for 25 bucks.
Do I think that will happen? No. Pretty sure it won't. But again - we do NOT know.
The bottom line is, if Denner gets SEVEN board seats, we are putting COMPLETE control in his hands, with NO idea what his plan is for the company.
So again, I'm voting for Denner's recommendation no matter what. But I *think* I might be more comfortable if Amarin offered him TWO board seats, and he accepted.
Now, if Denner comes out and clearly articulates what he would like to see happen (more than just "we need them to move faster and focus on cost containment, blah blah blah") prior to the proxy vote (and I like what I hear), then I might be inclined to be VERY supportive of total board control. But I really wish Denner would better articulate what his intentions are.
And please don't tell me "Denner's intentions are to maximize stockholder value". That's a given. He's a hedge fund manager, of course that's what he wants. But that doesn't articulate anything concrete. Despite what everything thinks, the Board and Management's intentions are to maximize shareholder value too. They just haven't done a great job of it yet. I just want to be sure that Denner is not going cause more harm than good.
Recent AMRN News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:10 PM
